An in-vitro evaluation of direct thrombin inhibitor and factor Xa inhibitor on tissue factor-induced thrombin generation and platelet aggregation: A comparison of dabigatran and rivaroxaban

Blood Coagulation and Fibrinolysis

Volumn 27, Issue 8, 2016, Pages 882-885

  Wan, Huaibin ^a   Yang, Yanmin ^a   Zhu, Jun ^a   Wu, Shuang ^a   Zhou, Zhou ^a   Huang, Bi ^a   Wang, Juan ^a   Shao, Xinghui ^a   Zhang, Han ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Dabigatran; Oral anticoagulant; Platelet aggregation; Rivaroxaban; Thrombin generation

Indexed keywords

DABIGATRAN; RIVAROXABAN; THROMBOPLASTIN; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; THROMBIN;

ADULT; AGED; ARTICLE; CALIBRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN EXPERIMENT; IC50; IN VITRO STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; THROMBIN TIME; THROMBOCYTE AGGREGATION; ANTAGONISTS AND INHIBITORS; BLOOD CLOTTING TEST; DRUG EFFECTS; MIDDLE AGED; PROCEDURES;

ADULT; ANTITHROMBINS; BLOOD COAGULATION TESTS; DABIGATRAN; FACTOR XA INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; RIVAROXABAN; THROMBIN;

EID: 84954349431     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0000000000000509     Document Type: Article

References (17)

1. Prescribing information of dabigatran etexilate. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt &folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf. [Accessed 17 April 2015].
2. Prescribing information of rivaroxaban. http://www.janssenmedicalinfo rmation.com/assets/pdf/products/files/Xarelto/pi/ENC-010330-11.pdf. [Accessed 17 April 2015].
3. Beasley BN, Unger EF, Temple R. Anticoagulant options: why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med 2011; 364:1788-1790.
4. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with nonvalvular atrial fibrillation. Europace 2013; 15:625-651.
5. Thompson CA. Oral direct factor Xa inhibitor gets FDA's OK. Am J Health Syst Pharm 2011; 68:1467.
6. Hosokawa K, Ohnishi T, Sameshima H, Miura N, Koide T, Maruyama I, Tanaka KA. Comparative evaluation of direct thrombin and factor Xa inhibitors with antiplatelet agents under flow and static conditions: an in vitro flow chamber model. PLoS One 2014; 9:e86491.
7. Gerotziafas GT, Elalamy I, Depasse F, Perzborn E, Samama MM. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J Thromb Haemost 2007; 5:886-888.
8. Dale B, Eikelboom JW, Weitz JI, Young E, Paikin JS, Coppens M, et al. Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction? J Thromb Thrombolysis 2013; 35:295-301.
9. Christersson C, Johnell M, Siegbahn A. The influence of direct thrombin inhibitors on the formation of platelet-leukocyte aggregates and tissue factor expression. Thromb Res 2010; 126:e327-e333.
10. Flierl U, Fraccarollo D, Micka J, Bauersachs J, Schafer A. The direct factor Xa inhibitor rivaroxaban reduces platelet activation in congestive heart failure. Pharmacol Res 2013; 74:49-55.
11. Guan J, Cong Y, Ren J, Zhu Y, Li L, Deng X, Bai J. Comparison between a new platelet count drop method PL-11, light transmission aggregometry, VerifyNow aspirin system and thromboelastography for monitoring short-term aspirin effects in healthy individuals. Platelets 2015; 26:25-30.
12. Narayanan S. Multifunctional roles of thrombin. Ann Clin Lab Sci 1999; 29:275-280.
13. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005; 3:1800-1814.
14. Wong PC, Jiang X. Apixaban a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin. Thromb Haemost 2010; 104:302-310.
15. Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011; 32:2781-2789.
16. Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009; 374:29-38.
17. Teitel JM, Bauer KA, Lau HK, Rosenberg RD. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 - 2 fragment and thrombin: antithrombin complex. Blood 1982; 59:1086-1097.